MAP1LC3B and cancer: Taking into consideration that treatment with lysosomal inhibitors results in accumulation of LC3B-II due to blockade of autophagosome-lysosome fusion, which leads to inhibition of LC3B degradation, establishing the biomarker potential of LC3B in different cancers might be useful for the selection of patients for treatment with CQ and its derivatives.